Market Overview

UPDATE: Bank Of America Reiterates On McKesson Ahead Of 4Q14 EPS

Share:
Related MCK
The Pharma Stocks Vitaliy Katsenelson Is Buying Now
7 Stocks To Watch Ahead Of The 60 Minutes DEA-Opioid Exposé

In a report published Tuesday, Bank of America analyst Robert M. Willoughby reiterated an Underperform rating on McKesson (NYSE: MCK), and raised the price target from $160.00 to $165.00.

In the report, Bank of America noted, “Rebounding profitability in MCK's core drug wholesaling operations, traction for its ancillary franchises, and capital deployment initiatives should drive industry-leading earnings growth over a leaner infrastructure. However, at valuation highs following the announcement of its Celesio acquisition, we see more attractive investment opportunities elsewhere.”

McKesson closed on Monday at $174.23.

Latest Ratings for MCK

DateFirmActionFromTo
Oct 2017Cowen & Co.UpgradesMarket PerformOutperform
Sep 2017RBC CapitalInitiates Coverage OnSector Perform
Sep 2017BairdUpgradesNeutralOutperform

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Bank of America Robert M. WilloughbyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MCK)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...